NDA 204410 · Actelion
Opsumit
Macitentan · Oral · Endothelin Receptor Antagonist
NovelOrphanLast checked: Nov 20, 2026Latest source record: Apr 2, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Oct 18, 2013
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
66
26 Phase 3, 6 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Macitentan" as an intervention, any sponsor and status, largest first.
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionPivotal-lookingActive, not recruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT04273945 · 935 participants · Start Jun 30, 2020 · Primary completion Oct 7, 2025
Drug: Macitentan 10 mg; Macitentan 37.5 mg and 2 more · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Scottsdale, Arizona; La Jolla, California · 274 sites in all
- Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial HypertensionPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00660179 · 742 participants · Start May 2008 · Primary completion Mar 2012
Drug: macitentan (ACT-064992); macitentan (ACT-064992) and 1 more · For: Pulmonary Arterial Hypertension
Sites: Birmingham, Alabama; Pheonix, Arizona; Los Angeles, California · 153 sites in all
- Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial HypertensionPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00667823 · 550 participants · Start Oct 17, 2008 · Primary completion Dec 7, 2020
Drug: Macitentan · For: Pulmonary Arterial Hypertension
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 158 sites in all
- Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01474109 · 289 participants · Start Dec 2011 · Primary completion Nov 2013
Drug: macitentan 3mg; macitentan 10mg and 1 more · For: Systemic Sclerosis; Ulcers
Sites: Tucson, Arizona; Los Angeles, California; Aventura, Florida · 77 sites in all
- Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT InstrumentPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01841762 · 284 participants · Start Apr 1, 2013 · Primary completion Nov 1, 2015
Drug: Macitentan · For: Pulmonary Arterial Hypertension
Sites: Birmingham, Alabama; Phoenix, Arizona; Beverly Hills, California · 81 sites in all
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionPivotal-lookingRecruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT05179876 · 280 participants (planned) · Start May 4, 2022 · Primary completion Jan 31, 2027
Drug: Macitentan; Selexipag and 1 more · For: Hypertension, Pulmonary
Sites: Minsk, Belarus; Leuven, Belgium; Sofia, Bulgaria · 45 sites in all
- Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsPivotal-lookingTerminated
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01474122 · 265 participants · Start Dec 2011 · Primary completion Feb 2014
Drug: Macitentan 3 mg; Macitentan 10 mg and 1 more · For: Digital Ulcers
- The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial HypertensionPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT02558231 · 247 participants · Start May 1, 2016 · Primary completion Aug 29, 2019
Drug: Macitentan; Tadalafil and 1 more · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 58 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Opsumit (Macitentan)
2024 spending
$1.23B
Beneficiaries
10,962
97,146 claims
Per beneficiary
$112,363
$420.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $768,656,729 |
| 2021 | $863,186,478 |
| 2022 | $816,890,224 |
| 2023 | $1,018,837,123 |
| 2024 | $1,231,721,758 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.
Grünig E, Jansa P, Fan F, et al. · J Am Coll Cardiol 2024 · Randomized Controlled Trial, Multicenter Study
- Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T, Adzerikho I, Channick RN, et al. · N Engl J Med 2013 · Clinical Trial, Phase III, Multicenter Study
- Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Chin KM, Sitbon O, Doelberg M, et al. · J Am Coll Cardiol 2021 · Clinical Trial, Phase III, Comparative Study
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
Erdogan M, Esatoglu SN, Kilickiran Avci B, et al. · Intern Emerg Med 2024 · Systematic Review, Meta-Analysis
- Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial.
Berger RMF, Dunbar Ivy D, Borissoff JI, et al. · J Pediatr 2026 · Randomized Controlled Trial, Multicenter Study
- Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.
McLaughlin VV, Hoeper MM, Channick RN, et al. · J Am Coll Cardiol 2018 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.